Liver-directed therapy in metastatic colorectal cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Helling TS, Martin M. Cause of death from liver metastases in colorectal cancer. Ann Surg Oncol. 2014;21:501–506.
   PubMed Web of Science ®Google Scholar
• Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2008;2. Art. No.: CD006039. doi: 10.1002/14651858.CD006039.pub4.
   PubMed Web of Science ®Google Scholar
• Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Registry of hepatic metastases. Surgery. 1988;103:278–288.
   PubMed Web of Science ®Google Scholar
• Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol off J Am Soc Clin Oncol. 2008;26:4828–4833.
   PubMed Web of Science ®Google Scholar
• D’Angelica MI, Correa-Gallego C, Paty PB, et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg. 2015;261:353–360.
   PubMed Web of Science ®Google Scholar
• Ardito F, Vellone M, Cassano A, et al. Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival. J Gastrointestinal Surg off J Soc Surg Aliment Tract. 2013;17:352–359.
   Google Scholar
• Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309–318; discussion 18–21.
   PubMed Web of Science ®Google Scholar
• Kemeny NE. Treatment of metastatic colon cancer: “the times they are A-changing”. J Clin Oncol off J Am Soc Clin Oncol. 2013;31:1913–1916.
   PubMed Web of Science ®Google Scholar
• Ensminger WD, Rosowsky A, Raso V, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2ʹ-deoxyuridine and 5-fluorouracil. Cancer Res. 1978;38:3784–3792.
   PubMed Web of Science ®Google Scholar
• Ensminger WD, Gyves JW. Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol. 1983;10:176–182.
   PubMed Web of Science ®Google Scholar
• Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy–an intergroup study. J Clin Oncol off J Am Soc Clin Oncol. 2002;20:1499–1505.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Seiter K, Niedzwiecki D, et al. A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer. Cancer. 1992;69:327–334.
   PubMed Web of Science ®Google Scholar
• Goere D, Deshaies I, de Baere T, et al. Prolonged survival of initially unresectable hepatic colorectal cancer patients treated with hepatic arterial infusion of oxaliplatin followed by radical surgery of metastases. Ann Surg. 2010;251:686–691.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Ychou M, Laplanche A, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol off J Am Soc Clin Oncol. 2005;23:4881–4887.
   PubMed Web of Science ®Google Scholar
• Allard MA, Sebagh M, Baillie G, et al. Comparison of complete pathologic response and hepatic injuries between hepatic arterial infusion and systemic administration of oxaliplatin in patients with colorectal liver metastases. Ann Surg Oncol. 2015;22:1925–1932.
   PubMed Web of Science ®Google Scholar
• Karanicolas PJ, Ko YJ. Hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the dawn of a new era? Ann Surg Oncol. 2017;24:6–7.
   PubMed Web of Science ®Google Scholar
• Dhir M, Jones HL, Shuai Y, et al. Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases: a case-control study. Ann Surg Oncol. 2017;24:150–158.
   PubMed Web of Science ®Google Scholar
• Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol off J Am Soc Clin Oncol. 2013;31:1931–1938.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341:2039–2048.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med. 2005;352:734–735.
   PubMed Web of Science ®Google Scholar
• Lygidakis NJ, Sgourakis G, Vlachos L, et al. Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results Prospective Randomized Study Hepato-Gastroenterology. 2001;48:1685–1691.
   Google Scholar
• Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg. 1998;228:756–762.
   PubMed Web of Science ®Google Scholar
• Kusunoki M, Yanagi H, Noda M, et al. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer. 2000;89:1228–1235.
   PubMed Web of Science ®Google Scholar
• Tono T, Ohzato H, Hasuike Y, et al. The efficacy and limitation of hepatic arterial infusion chemotherapy for colorectal liver metastases. Gan to Kagaku Ryoho [Cancer Chemother]. 1999;26:1741–1746.
   PubMedGoogle Scholar
• Goere D, Benhaim L, Bonnet S, et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Ann Surg. 2013;257:114–120.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Jarnagin W, Gonen M, et al. Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. J Clin Oncol off J Am Soc Clin Oncol. 2003;21:3303–3309.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Capanu M, D’Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol off J Eur Soc Med Oncol. 2009;20:1236–1241.
   PubMed Web of Science ®Google Scholar
• Alberts SR, Roh MS, Mahoney MR, et al. Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N9945/CI-66. J Clin Oncol off J Am Soc Clin Oncol. 2010;28:853–858.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Jarnagin WR, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol off J Am Soc Clin Oncol. 2011;29:884–889.
   PubMed Web of Science ®Google Scholar
• Cercek A, D’Angelica M, Power D, et al. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab. Ann Surg Oncol. 2014;21:479–486.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Chou JF, Boucher TM, et al. Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. J Surg Oncol. 2016;113:477–484.
   PubMed Web of Science ®Google Scholar
• Groot Koerkamp B, Sadot E, Kemeny NE, et al. Perioperative hepatic arterial infusion pump chemotherapy Q:1; 2 Is associated with longer survival after resection of colorectal liver metastases: a propensity score analysis of 2,368 consecutive patients. J Clin Oncol off J Am Soc Clin Oncol. 2017;35:1938–1944.
   PubMed Web of Science ®Google Scholar
• Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev. 2004;2. Art. No.: CD003770. DOI: 10.1002/14651858.CD003770.pub2.
   PubMed Web of Science ®Google Scholar
• Liu W, Song QK, Xing BC. A systematic review and meta-analysis to reappraise the role of adjuvant hepatic arterial infusion for colorectal cancer liver metastases. Int J Colorectal Dis. 2015;30:1091–1102.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhong Y, Weixin N, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery. Ann Surg. 2007;245:583–590.
   PubMed Web of Science ®Google Scholar
• Feng WM, Tang CW, Huang SX, et al. Prophylactic adjuvant hepatic arterial infusion chemotherapy reduced hepatic metastases from stage III colorectal cancer after curative resection. Hepato-Gastroenterology. 2012;59:1087–1090.
   PubMedGoogle Scholar
• Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol off J Am Soc Clin Oncol. 2009;27:3109–3116.
   PubMed Web of Science ®Google Scholar
• Xu J, Xia J, Gu Y, et al. Effect of preoperative hepatic and regional arterial chemotherapy on metachronous liver metastasis after curative colorectal cancer resection: a prospective, multicenter, randomized controlled trial. 2015 Gastrointestinal Cancers Symposium; 2015.
   Google Scholar
• Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol off J Am Soc Clin Oncol. 2007;25:4575–4580.
   PubMed Web of Science ®Google Scholar
• Wei AC, Greig PD, Grant D, et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13:668–676.
   PubMed Web of Science ®Google Scholar
• Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–135.
   PubMed Web of Science ®Google Scholar
• de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250:440–448.
   PubMed Web of Science ®Google Scholar
• Morris EJ, Forman D, Thomas JD, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg. 2010;97:1110–1118.
   PubMed Web of Science ®Google Scholar
• Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol off J Am Soc Clin Oncol. 2006;24:3939–3945.
   PubMed Web of Science ®Google Scholar
• Adam R, Wicherts DA, De Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol off J Am Soc Clin Oncol. 2008;26:1635–1641.
   PubMed Web of Science ®Google Scholar
• Adam R, Pascal G, Castaing D, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240:1052–1061; discussion 61–64.
   Web of Science ®Google Scholar
• Jarnagin WR, Conlon K, Bodniewicz J, et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer. 2001;91:1121–1128.
   PubMed Web of Science ®Google Scholar
• Folprecht G, Grothey A, Alberts S, et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol off J Eur Soc Med Oncol. 2005;16:1311–1319.
   PubMed Web of Science ®Google Scholar
• Beppu T, Hayashi N, Masuda T, et al. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res. 2010;30:1015–1020.
   PubMed Web of Science ®Google Scholar
• Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644–657; discussion 57–58.
   Web of Science ®Google Scholar
• Delaunoit T, Alberts SR, Sargent DJ, et al. Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann Oncol off J Eur Soc Med Oncol. 2005;16:425–429.
   PubMed Web of Science ®Google Scholar
• Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol off J Eur Soc Med Oncol. 2004;15:933–939.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol off J Am Soc Clin Oncol. 2007;25:1670–1676.
   PubMed Web of Science ®Google Scholar
• Hokuto D, Nomi T, Yamato I, et al. The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy. J Surg Oncol. 2016;114:959–965.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–1215.
   PubMed Web of Science ®Google Scholar
• Lam VW, Spiro C, Laurence JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012;19:1292–1301.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Niedzwiecki D, Hollis DR, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol off J Am Soc Clin Oncol. 2006;24:1395–1403.
   PubMed Web of Science ®Google Scholar
• Rougier P, Laplanche A, Huguier M, et al. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol off J Am Soc Clin Oncol. 1992;10:1112–1118.
   PubMed Web of Science ®Google Scholar
• Hohn DC, Stagg RJ, Friedman MA, et al. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol off J Am Soc Clin Oncol. 1989;7:1646–1654.
   PubMed Web of Science ®Google Scholar
• Kemeny NE, Melendez FD, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol off J Am Soc Clin Oncol. 2009;27:3465–3471. • Study exploring the role and effectiveness of combination HAI and systemic chemotherapy in converting inoperable colorectal liver metastases to resection.
   PubMed Web of Science ®Google Scholar
• Levi FA, Boige V, Hebbar M, et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol off J Eur Soc Med Oncol. 2016;27:267–274.
   PubMed Web of Science ®Google Scholar
• Diaz-Nieto R, Fenwick S, Malik H, et al. Defining the optimal use of ablation for metastatic colorectal cancer to the liver without high-level evidence. Curr Treat Options Oncol. 2017;18:8.
   PubMed Web of Science ®Google Scholar
• Poston G. Cryosurgery for colorectal liver metastases. Hepato-Gastroenterology. 2001;48:323–324.
   PubMedGoogle Scholar
• Brown RE, Martin RC 2nd, Scoggins CR. Ablative therapies for colorectal liver metastases. Surg Oncol Clin N Am. 2011;20:259–271, vii.
   PubMed Web of Science ®Google Scholar
• Pathak S, Jones R, Tang JM, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Disease off J Assoc Coloproctology G B Irel. 2011;13:e252–65.
   PubMed Web of Science ®Google Scholar
• Stattner S, Jones RP, Yip VS, et al. Microwave ablation with or without resection for colorectal liver metastases. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2013;39:844–849. • Study examines the role of microwave ablation as an adjunctive therapy to hepatic resection of colorectal liver metastases.
   Google Scholar
• Correa-Gallego C, Fong Y, Gonen M, et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol. 2014;21:4278–4283.
   PubMed Web of Science ®Google Scholar
• Narayanan G. Irreversible electroporation for treatment of liver cancer. Gastroenterol Hepatol. 2011;7:313–316.
   Google Scholar
• Scheffer HJ, Melenhorst MC, Echenique AM, et al. Irreversible electroporation for colorectal liver metastases. Tech Vasc Interv Radiol. 2015;18:159–169.
   PubMedGoogle Scholar
• Siperstein AE, Berber E, Ballem N, et al. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246:559–565; discussion 65–67.
   PubMed Web of Science ®Google Scholar
• Hur H, Ko YT, Min BS, et al. Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg. 2009;197:728–736.
   PubMed Web of Science ®Google Scholar
• Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–825; discussion 25–27.
   Web of Science ®Google Scholar
• Hamada A, Yamakado K, Nakatsuka A, et al. Radiofrequency ablation for colorectal liver metastases: prognostic factors in non-surgical candidates. Jpn J Radiol. 2012;30:567–574.
   PubMed Web of Science ®Google Scholar
• Karanicolas PJ, Jarnagin WR, Gonen M, et al. Long-term outcomes following tumor ablation for treatment of bilateral colorectal liver metastases. JAMA Surg. 2013;148:597–601.
   PubMed Web of Science ®Google Scholar
• Evrard S, Rivoire M, Arnaud J, et al. Unresectable colorectal cancer liver metastases treated by intraoperative radiofrequency ablation with or without resection. Br J Surg. 2012;99:558–565.
   PubMed Web of Science ®Google Scholar
• Aissou S, Cartier V, Hamy A, et al. Radiofrequency in the management of colorectal liver metastases: a 10-year experience at a single center. Surg Technol Int. 2016;Xxix:99–105.
   PubMedGoogle Scholar
• Imai K, Allard MA, Castro Benitez C, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104:570–579.
   PubMed Web of Science ®Google Scholar
• Ruers T, Punt C, Van Coevorden F, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol off J Eur Soc Med Oncol. 2012;23:2619–2626.
   PubMed Web of Science ®Google Scholar
• Ruers T, Van Coevorden F, Punt CJ, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. JNCI Journal of the National Cancer Institute. 2017;109(9):djx015. http://doi.org/10.1093/jnci/djx015.
   PubMedGoogle Scholar
• Fiorentini G, Aliberti C, Benea G, et al. TACE of liver metastases from colorectal cancer adopting irinotecan-eluting beads: beneficial effect of palliative intra-arterial lidocaine and post-procedure supportive therapy on the control of side effects. Hepato-Gastroenterology. 2008;55:2077–2082.
   PubMed Web of Science ®Google Scholar
• Gruber-Rouh T, Naguib NN, Eichler K, et al. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer. 2014;134:1225–1231.
   PubMed Web of Science ®Google Scholar
• Riemsma RP, Bala MM, Wolff R, et al. Transarterial (chemo)embolisation versus no intervention or placebo intervention for liver metastases. Cochrane Database Syst Rev. 2012;9. Art. No.: CD009498. doi: 10.1002/14651858.CD009498.pub2.
   PubMed Web of Science ®Google Scholar
• Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC Bead(R), drug-eluting bead loaded with irinotecan: results of a phase II clinical study. Anticancer Res. 2011;31:4581–4587.
   PubMed Web of Science ®Google Scholar
• Scevola G, Loreni G, Rastelli M, et al. Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Med Oncol. 2017;34:37.
   PubMed Web of Science ®Google Scholar
• Fiorentini G, Aliberti C, Tilli M, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32:1387–1395.
   PubMed Web of Science ®Google Scholar
• Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interventional Radiol JVIR. 2013;24:1209–1217.
   PubMed Web of Science ®Google Scholar
• Martin RC 2nd, Scoggins CR, Schreeder M, et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121:3649–3658.
   PubMed Web of Science ®Google Scholar
• Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–821.
   PubMed Web of Science ®Google Scholar
• Comito T, Clerici E, Tozzi A, et al. Liver metastases and SBRT: a new paradigm? Rep Pract Oncol Radiother J Greatpoland Cancer Center Poznan Pol Soc Radiat Oncol. 2015;20:464–471.
   PubMedGoogle Scholar
• Hoyer M, Roed H, Traberg Hansen A, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45:823–830.
   PubMed Web of Science ®Google Scholar
• Chang DT, Swaminath A, Kozak M, et al. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011;117:4060–4069.
   PubMed Web of Science ®Google Scholar
• Klement RJ, Guckenberger M, Alheid H, et al. Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2017;123:227–233.
   PubMed Web of Science ®Google Scholar
• Price TJ, Townsend A. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch Surg (Chicago, Ill: 1960). 2008;143:313–314.
   PubMedGoogle Scholar
• Kennedy AS, Nutting C, Coldwell D, et al. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552–1563.
   PubMed Web of Science ®Google Scholar
• Yorke ED, Jackson A, Fox RA, et al. Can current models explain the lack of liver complications in Y-90 microsphere therapy? Clin Cancer Res off J Am Assoc Cancer Res. 1999;5:3024s–30s.
   PubMed Web of Science ®Google Scholar
• Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interventional Radiol JVIR. 2009;20:1121–1130; quiz 31.
   Web of Science ®Google Scholar
• Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538–1546.
   PubMed Web of Science ®Google Scholar
• Kennedy AS, McNeillie P, Dezarn WA, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494–1500.
   PubMed Web of Science ®Google Scholar
• Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interventional Radiol JVIR. 2007;18:1375–1382.
   PubMed Web of Science ®Google Scholar
• Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919–924.
   PubMed Web of Science ®Google Scholar
• Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol. 2008;31:431–438.
   PubMed Web of Science ®Google Scholar
• Hendlisz A, Van Den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol off J Am Soc Clin Oncol. 2010;28:3687–3694.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Van Hazel GA, Morgan B, et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol off J Am Soc Clin Oncol. 2007;25:1099–1106.
   PubMed Web of Science ®Google Scholar
• van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol off J Am Soc Clin Oncol. 2016;34:1723–1731.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer. 2015;14:296–305.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Wasan HS, Love SB, et al. FOXFIRE: a phase III clinical trial of chemo-radio-embolisation as first-line treatment of liver metastases in patients with colorectal cancer. Clin Oncol (R Coll Radiol). 2008;20:261–263.
   PubMed Web of Science ®Google Scholar
• Zacharias AJ, Jayakrishnan TT, Rajeev R, et al. Comparative effectiveness of hepatic artery based therapies for unresectable colorectal liver metastases: a meta-analysis. Plos ONE. 2015;10:e0139940.
   Web of Science ®Google Scholar
• Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol. 2001;8:347–353.
   PubMed Web of Science ®Google Scholar
• Karanicolas PJ, Metrakos P, Chan K, et al. Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. Curr Oncol (Toronto, Ont). 2014;21:e129–36.
   PubMed Web of Science ®Google Scholar
• Sharma RA, Wasan H, Van Hazel GA, et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. Journal of Clinical Oncology. 2017;35:15_suppl, 3507-3507.
   Google Scholar